Search results for " Nonalcoholic"

showing 10 items of 24 documents

Digital Pathology Enables Automated and Quantitative Assessment of Inflammatory Activity in Patients with Chronic Liver Disease

2021

Traditional histological evaluation for grading liver disease severity is based on subjective and semi-quantitative scores. We examined the relationship between digital pathology analysis and corresponding scoring systems for the assessment of hepatic necroinflammatory activity. A prospective, multicenter study including 156 patients with chronic liver disease (74% nonalcoholic fatty liver disease-NAFLD, 26% chronic hepatitis-CH etiologies) was performed. Inflammation was graded according to the Nonalcoholic Steatohepatitis (NASH) Clinical Research Network system and METAVIR score. Whole-slide digital image analysis based on quantitative (I-score: inflammation ratio) and morphometric (C-sco…

Liver CirrhosisMalenonalcoholic fatty liver diseaseMiddle AgedFibrosisMicrobiologyBiochemistryArticleQR1-502digital pathology; inflammation; nonalcoholic fatty liver disease; chronic hepatitisLiverNon-alcoholic Fatty Liver DiseaseinflammationHumanschronic hepatitisdigital pathologyMolecular BiologyBiomolecules
researchProduct

Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease

2017

Abstract In an increasing proportion of cases, hepatocellular carcinoma (HCC) develops in patients with nonalcoholic fatty liver disease (NAFLD). Mutations in telomerase reverse transcriptase (hTERT) are associated with familial liver diseases. The aim of this study was to examine telomere length and germline hTERT mutations as associated with NAFLD‐HCC. In 40 patients with NAFLD‐HCC, 45 with NAFLD‐cirrhosis and 64 healthy controls, peripheral blood telomere length was evaluated by qRT‐PCR and hTERT coding regions and intron–exon boundaries sequenced. We further analyzed 78 patients affected by primary liver cancer (NAFLD‐PLC, 76 with HCC). Enrichment of rare coding mutations (allelic frequ…

MaleCancer ResearchHepatocellular carcinomaSeverity of Illness IndexGermlineLoss of heterozygosityCohort StudiesLiver disease0302 clinical medicineNon-alcoholic Fatty Liver DiseaseNuclear Medicine and ImagingNonalcoholic fatty liver disease80 and overLeukocytesTelomeraseTelomere ShorteningOriginal ResearchCancer BiologyAged 80 and overHepatocellular carcinoma; Nonalcoholic fatty liver; Rare germline mutations; Telomerase reverse transcriptase; Telomere; Oncology; Radiology Nuclear Medicine and Imaging; Cancer ResearchtelomereLiver Neoplasmstelomerase reverse transcriptaseMiddle Aged3. Good healthPhenotypeOncology030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyFemaleDisease SusceptibilityRadiologySequence AnalysisRare germline mutationCarcinoma HepatocellularMononuclearBiology03 medical and health sciencesGermline mutationHepatocellular carcinoma; Nonalcoholic fatty liver; Rare germline mutations; Telomerase reverse transcriptase; Telomere; Aged; Aged 80 and over; Alleles; Amino Acid Substitution; Carcinoma Hepatocellular; Cohort Studies; Computational Biology; Disease Susceptibility; Female; Genetic Association Studies; Humans; Leukocytes Mononuclear; Liver Neoplasms; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Phenotype; Sequence Analysis DNA; Severity of Illness Index; Telomerase; Telomere; Telomere Shortening; Germ-Line Mutationmedicinenonalcoholic fatty liverHumansRadiology Nuclear Medicine and imagingTelomerase reverse transcriptaseAllelesGenetic Association StudiesGerm-Line MutationAgedrare germline mutationsCarcinomaComputational BiologyHepatocellularDNASequence Analysis DNAmedicine.diseasedigestive system diseasesTelomereAmino Acid SubstitutionCancer researchLeukocytes MononuclearCancer Medicine
researchProduct

Nonalcoholic fatty liver and metabolic syndrome in Italy: Results from a multicentric study of the Italian Arteriosclerosis society

2013

Nonalcoholic fatty liver disease (NAFLD) is associated with all the components of metabolic syndrome (MS) and might to be considered an additional component of MS itself. The Italian Society for the Study of Atherosclerosis (SISA) in 2005 started a research project aimed to study the NAFLD, using ultrasound (US), in nondiabetic MS subjects matching at least one of the ATP III criteria for HDL-C or triglycerides [TG]. Prevalence of US-NAFLD and its associated risk factors and prevalence of hypertransaminasemia and its possible determinants were evaluated. NAFLD prevalence was 0.78. Men with steatosis compared to men without steatosis were younger (P < 0.05) with higher TG (P < 0.03), homeost…

MaleSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismNonalcoholic fatty liverSex FactorSettore MED/13 - EndocrinologiaBody Mass IndexEndocrinologyNon-alcoholic Fatty Liver DiseaseRisk FactorsNonalcoholic fatty liver diseaseAtherosclerosis; Metabolic Syndrome X; Sex Factors; Humans; Lipids; Aged; Fatty Liver; Non-alcoholic Fatty Liver Disease; Body Mass Index; Italy; Logistic Models; Risk Factors; Liver; Middle Aged; Female; MaleUltrasonographyMulticentric studyMetabolic Syndrome XFatty liverGeneral MedicineArteriosclerosisLipidMiddle AgedLipidsMetabolic syndromeDiabetes and MetabolismItalyLiverAtherosclerosiFemaleHumanmedicine.medical_specialtyLogistic ModelNonalcoholic fatty liver Metabolic syndrome Lipids Multicentric studyInsulin resistanceSex FactorsDiabetes mellitusInternal medicinemedicineInternal MedicineHumansLipids; Metabolic syndrome; Multicentric study; Nonalcoholic fatty liver; Aged; Body Mass Index; Fatty Liver; Female; Humans; Italy; Lipids; Liver; Logistic Models; Male; Metabolic Syndrome X; Middle Aged; Non-alcoholic Fatty Liver Disease; Risk Factors; Sex Factors; Atherosclerosis; Endocrinology; Internal Medicine; Endocrinology Diabetes and MetabolismAgedbusiness.industryRisk Factornutritional and metabolic diseasesAmbientalemedicine.diseaseAtherosclerosisFatty LiverEndocrinologyLogistic ModelsMetabolic syndromeSteatosisbusinessBody mass index
researchProduct

Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: The ITA.LI.CA database

2021

BackgroundMetabolic dysfunction-associated fatty liver disease (MAFLD) represents a new inclusive definition of the whole spectrum of liver diseases associated to metabolic disorders. The main objective of this study was to compare patients with MAFLD and non-MAFLD with hepatocellular carcinoma (HCC) included in a nationally representative cohort.MethodsWe analysed 6882 consecutive patients with HCC enrolled from 2002 to 2019 by 23 Italian Liver Cancer centres to compare epidemiological and future trends in three subgroups: pure, single aetiology MAFLD (S-MAFLD); mixed aetiology MAFLD (metabolic and others, M-MAFLD); and non-MAFLD HCC.ResultsMAFLD was diagnosed in the majority of patients w…

MaleSettore MED/12 - GastroenterologiaCarcinoma HepatocellularLiver Neoplasmsnonalcoholic steatohepatitis.Gastroenterologyhepatocellular carcinomadigestive system diseaseshepatocellular carcinoma; nonalcoholic steatohepatitisNon-alcoholic Fatty Liver DiseaseRisk FactorsHumansnonalcoholic steatohepatitisneoplasms
researchProduct

Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis

2003

Familial hypobetalipoproteinemia (FHBL) subjects may develop fatty liver. Liver fat was assessed in 21 FHBL with six different apolipoprotein B (apoB) truncations (apoB-4 to apoB-89) and 14 controls by magnetic resonance spectroscopy (MRS). Liver fat percentages were 16.7 +/- 11.5 and 3.3 +/- 2.9 (mean +/- SD) (P = 0.001). Liver fat percentage was positively correlated with body mass index, waist circumference, and areas under the insulin curves of 2 h glucose tolerance tests, suggesting that obesity may affect the severity of liver fat accumulation in both groups. Despite 5-fold differences in liver fat percentage, mean values for obesity and insulin indexes were similar. Thus, for similar…

MaleVery low-density lipoproteinSettore MED/09 - Medicina InternaApolipoprotein Bmedicine.medical_treatmentPalmitic AcidLipoproteins VLDLSeverity of Illness IndexTriglyceridevery low density lipoprotein assemblyBiochemistryBody Mass IndexMagnetic resonence spectroscopy; Nonalcoholic fatty liver; Nonesterified fatty acids; Very low density lipoprotein assembly; Adult; Body Mass Index; Dietary Fats; Fatty Liver; Female; Glucose Tolerance Test; Humans; Hypobetalipoproteinemias; Insulin Resistance; Lipoproteins VLDL; Liver Diseases; Male; Middle Aged; Obesity; Palmitic Acids; Severity of Illness Index; Triglycerides; EndocrinologyHypobetalipoproteinemiaschemistry.chemical_compoundEndocrinologyDietary FatGlucose tolerance testmedicine.diagnostic_testbiologyChemistryLiver DiseasesLiver DiseaseFatty liverMiddle AgedFemalemagnetic resonence spectroscopyHumanAdultmedicine.medical_specialtyPalmitic Acidsnonesterified fatty acidsQD415-436Internal medicinemedicinenonalcoholic fatty liverHumansObesityTriglyceridesTriglycerideInsulinNonesterified fatty acidCell BiologyGlucose Tolerance Testmedicine.diseaseDietary FatsFatty LiverEndocrinologybiology.proteinHypobetalipoproteinemiaInsulin ResistanceSteatosisHypobetalipoproteinemiaJournal of Lipid Research
researchProduct

Clinical and biochemical determinants of the extent of liver steatosis in type 2 diabetes mellitus

2015

Objective Nonalcoholic fatty liver disease is very frequent in both type 2 diabetes mellitus (T2DM) and the metabolic syndrome (MS), which share clinical and metabolic characteristics. Whether and to which extent these characteristics can predict the degree of liver steatosis are not entirely clear. Patients and methods We determined liver fat (divided into four classes) by standard sonographic images, and clinical and biochemical variables, in 60 consecutive patients with T2DM and with features of the MS. We examined both simple and multiple correlations between the degree of liver steatosis and the variables measured. Results Increased liver fat (defined as &gt;5% of liver mass) was detec…

Malenonalcoholic fatty liver diseasemedicine.medical_specialtytype 2 diabetes mellitusmedicine.medical_treatmentSettore MED/50 - Scienze Tecniche Mediche ApplicateGastroenterologyleptinliver steatosispredictive modelInsulin resistanceNon-alcoholic Fatty Liver DiseaseInternal medicineinsulin resistanceNonalcoholic fatty liver diseasemedicineHumansInsulinAdiposityAgedUltrasonographyvisceral adiposityGlycated HemoglobinMetabolic SyndromeSettore SECS-S/06 - Metodi mat. dell'economia e Scienze Attuariali e FinanziarieModels StatisticalAnthropometryHepatologybusiness.industryInsulinHemoglobin A1c; insulin resistance; leptin; liver steatosis; metabolic control; multiple regression analysis; nonalcoholic fatty liver disease; predictive model; type 2 diabetes mellitus; visceral adiposity;GastroenterologyType 2 Diabetes MellitusHemoglobin A1c; insulin resistance; leptin; liver steatosis; metabolic control; multiple regression analysis; nonalcoholic fatty liver disease; predictive model; type 2 diabetes mellitus; visceral adiposity; Gastroenterology; Hepatologymetabolic controlmultiple regression analysisMiddle AgedHepatologymedicine.diseaseEndocrinologyDiabetes Mellitus Type 2Hemoglobin A1cMetabolic control analysisFemaleWaist CircumferenceSteatosisMetabolic syndromebusinesshemoglobin A1c leptin liver steatosis metabolic control multiple regression analysis nonalcoholic fatty liver disease insulin resistance predictive model type 2 diabetes mellitus visceral adiposity
researchProduct

Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib

2021

Background Hepatocellular carcinoma (HCC) treatment remains a big challenge in the field of oncology. The liver disease (viral or not viral) underlying HCC turned out to be crucial in determining the biologic behavior of the tumor, including its response to treatment. The aim of this analysis was to investigate the role of the etiology of the underlying liver disease in survival outcomes. Patients and methods We conducted a multicenter retrospective study on a large cohort of patients treated with lenvatinib as first-line therapy for advanced HCC from both Eastern and Western institutions. Univariate and multivariate analyses were performed. Results Among the 1232 lenvatinib-treated HCC pat…

OncologyPhenylurea CompoundatezolizumabCancer Researchmedicine.medical_specialtyCarcinoma HepatocellularQuinolinelenvatinibbevacizumabchemistry.chemical_compoundLiver diseaseRetrospective StudieNon-alcoholic Fatty Liver DiseaseInternal medicineMedicineHumansnonalcoholic steatohepatitisOriginal ResearchRetrospective StudiesUnivariate analysisSettore MED/12 - GastroenterologiaPerformance statusbusiness.industryPhenylurea CompoundsHazard ratioLiver NeoplasmsRetrospective cohort studyHepatitis Chepatocellular carcinomamedicine.diseasePrognosisdigestive system diseasesadvanced hepatocarcinoma; atezolizumab; bevacizumab; hepatitis C; hepatocellular carcinoma; immunotherapy; lenvatinib; nonalcoholic steatohepatitis; sorafenibadvanced hepatocarcinomaOncologychemistryLiver NeoplasmHepatocellular carcinomanonalcoholic steatohepatitiQuinolinessorafenibimmunotherapyhepatitis CbusinessLenvatinibHuman
researchProduct

Effectiveness of lifestyle interventions in NAFLD (nonalcoholic fatty liver disease) - how are clinical trials affected?

2020

Pharmacologymedicine.medical_specialtyClinical Trials as Topicbusiness.industryNAFLD - Nonalcoholic Fatty Liver DiseaseGeneral MedicineClinical trialPharmacotherapyNon-alcoholic Fatty Liver DiseaseResearch DesignInternal medicineLifestyle interventionmedicineHumansPharmacology (medical)businessLife StyleExpert opinion on investigational drugs
researchProduct

Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes.

2020

Background: Naturally occurring variation in Membrane-bound O-acyltransferase domain-containing 7 (MBOAT7), encoding for an enzyme involved in phosphatidylinositol acyl-chain remodelling, has been associated with fatty liver and hepatic disorders. Here, we examined the relationship between hepatic Mboat7 down-regulation and fat accumulation. Methods: Hepatic MBOAT7 expression was surveyed in 119 obese individuals and in experimental models. MBOAT7 was acutely silenced by antisense oligonucleotides in C57Bl/6 mice, and by CRISPR/Cas9 in HepG2 hepatocytes. Findings: In obese individuals, hepatic MBOAT7 mRNA decreased from normal liver to steatohepatitis, independently of diabetes, inflammatio…

Research paperTGFβ Transforming Growth Factor BetaIntracellular SpaceCRISPR Clustered Regularly Interspaced Short Palindromic RepeatshHEPS Human HepatocytesMice0302 clinical medicineLPIAT1DAG Diacylglyceroli.p. Intraperitonealmedia_commonFatty AcidsGeneral Medicine3. Good health030220 oncology & carcinogenesisHOMA-IR homeostasis Model Assessment of Insulin ResistanceMPO morpholinolcsh:Medicine (General)medicine.medical_specialtyPE Phosphatidyl-EthanolamineNashGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesTNFα tumor Necrosis Factor AlphaLDL Low Density LipoproteinsHyperinsulinismNAFLDSD Standard Dietmedia_common.cataloged_instanceHumansCPT1 Carnitine Palmitoyltransferase IPhosphatidylinositolGene SilencingEuropean unionVLDL Very Low Density Lipoproteinlcsh:RhHSC Human Hepatic Stellate Cellsmedicine.diseaseLipid MetabolismOA Oleic AcidCI Confidence IntervalMboat7 Membrane bound O-acyltransferase domain containing 7MCD methionine choline deficient diet030104 developmental biologyEndocrinologychemistryCDP Cytidine-DiphosphateFOXO1 Forkhead Box protein O1NAFLD nonalcoholic fatty liver diseaseSteatohepatitisBMI Body Mass IndexCL CardiolipinAcyltransferases0301 basic medicineAlcoholic liver diseaseCXCL10 C-X-C Motif Chemokine 10lcsh:Medicinechemistry.chemical_compoundNon-alcoholic Fatty Liver DiseaseIFG Impaired Fasting GlucoseAPOB Apolipoprotein BNonalcoholic fatty liver diseasePIP Phosphatidyl-Inositol-PhosphateSteatohepatitisqRT-PCR quantitative Real Time Polymerase Chain ReactionMice Knockoutlcsh:R5-920ORO Oil Red O StainingPI PhosphatidylinositolFatty liverTM6SF2 Transmembrane 6 Superfamily Member 2PhospholipidTAG TriglyceridesNASH Nonalcoholic SteatohepatitisLipogenesisLPA Lyso-Phosphatidic AcidPhosphatidylinositolSignal TransductionPS Phosphatidyl-SerinePA Palmitic AcidALD alcoholic liver diseasePC Phosphatidylcholinei.v. IntravenousFATP1 Fatty Acid Transport Protein 1Models BiologicalInternal medicinemedicineAnimalsNonalcoholic fatty liver diseasePPARα Peroxisome Proliferator-Activated Receptor alphaObesityG3P Glyceraldehyde-3-PhosphateSREBP1c Sterol Regulatory Element-Binding Protein 1HDL High Density Lipoproteinsbusiness.industryPI3K Phosphatidylinositol 3 KinaseMembrane ProteinsNHEJ Non-Homologues End JoiningPNPLA3 Patatin-like Phospholipase Domain-containing-3MTTP Microsomal Triglyceride Transfer ProteinLPIAT1 Lysophosphatidylinositol Acyltransferase 1TMC4 Transmembrane Channel-Like 4Disease Models AnimalGene Expression RegulationHepatocytesFOXA2 Forkhead Box A2mTOR mammalian target of RapamycinSteatosisInsulin ResistancebusinessPG Phosphatidyl-GlycerolFABP1 Fatty Acid-Binding Protein 1 FAS Fatty Acid SynthaseT2DM Type 2 Diabetes MellitusEBioMedicine
researchProduct

Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice.

2020

Nonalcoholic fatty liver disease (NAFLD) is a clinical condition that encompasses various forms of liver damage not caused by chronic alcohol consumption. In the absence of other etiologies, it ranges from ste- atosis to nonalcoholic steatohepatitis and cirrhosis. The prevalence of NAFLD has considerably increased over the last years owing to the current lifestyle (unhealthy diet and sedentarism). Besides, it is associated with metabolic risk factors such as obesity, arterial hypertension, dyslipidemia, and type 2 diabetes. Given the poor prognosis of patients with advanced NAFLD, a practical therapeutic approach is necessary to halt its natural history. However, no licensed drugs have been…

medicine.medical_specialtyCirrhosisbusiness.industrynutritional and metabolic diseasesDiseaseType 2 diabetesComorbiditymedicine.diseaseObesitydigestive system diseasesArterial hypertension Dyslipidemia Nonalcoholic fatty liver disease Type 2 diabetes Comorbidity Humans Obesity Weight Loss Diabetes Mellitus Type 2 Non-alcoholic Fatty Liver DiseaseDiabetes Mellitus Type 2Weight lossNon-alcoholic Fatty Liver DiseaseInternal medicineNonalcoholic fatty liver diseaseWeight LossInternal MedicinemedicineHumansObesitymedicine.symptomSteatosisbusinessDyslipidemiaPolish archives of internal medicine
researchProduct